---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033726"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:20:55.216557+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics names Toby Ferguson as Chief Medical Officer

## Summary
- Employment starts March 25, 2024; base salary $485,000, target bonus 40%.
- Granted inducement option for 210k shares and RSU for 105k shares, both time-vesting.
- Dr. Ferguson previously VP, Head of Neuromuscular Development at Biogen (2013-2024).
- Severance provides 12 months base salary and pro-rata bonus if terminated without cause or for good reason within 12 months post sale event.
- At-will employment; standard non-compete and confidentiality obligations.

## SEC filing metadata
- accession: 0001104659-24-033726
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/0001104659-24-033726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/tm247944d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033726
- JSON: https://secwatch.observer/filing/0001104659-24-033726.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.